Roche
Novartis challenges Roche with MabThera biosimilar
January 11, 2011Research and Development Lonza MabThera, Novartis, Roche, Teva, biosimilar, rituximab
Novartis’ generics unit Sandoz has begun mid-stage trials of a biosimilar version of Roche’s blockbuster drug MabThera. The phase II …
Study highlights Avastin heart failure risk
January 6, 2011Research and Development, Sales and Marketing Roche, avastin, bevacizumab, breast cancer
A new study confirms that Roche’s Avastin is linked to a small but significant increased risk of heart failure in …
Roche to challenge FDA on Avastin
December 21, 2010Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer
Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …
Boehringer puts afatinib head-to-head with Herceptin
December 10, 2010Research and Development BIBW 2992, Boehringer Ingelheim, Herceptin, Roche, Tovok, afatinib, breast cancer
Boehringer Ingelheim has set up a showdown between one of its pipeline oncology products and Roche’s Herceptin. It has started …
Roche highlights R&D promise after setbacks
December 9, 2010Research and Development MS, Roche, oncology, personalised medicine, schizophrenia
Roche has presented its pipeline to shareholders to boost confidence that it can sustain the spectacular growth of recent years. …
NICE no for Avastin in breast cancer
December 8, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, breast cancer, health technology assessment, hta
NICE has refused to back Roche’s Avastin for use in breast cancer patients citing the blockbuster drug’s high cost and …
Roche’s MabThera successor shows phase II promise
December 6, 2010Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia
The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …
NICE recommends MabThera for non-Hodgkin’s lymphoma
December 6, 2010Sales and Marketing MabThera, NICE, Rituxan, Roche, non-Hodgkin’s lymphoma, rituximab
NICE has given a preliminary green-light to Roche’s MabThera for use as a maintenance therapy for non-Hodgkin’s lymphoma. The Institute’s …
Roche set to challenge NICE Tarceva decision
November 25, 2010Sales and Marketing NICE, Roche, Roche UK, Tarceva, erlotinib, lung cancer
NICE has again rejected Roche’s lung cancer drug Tarceva in its second round of draft guidance. Tarceva (erlotinib) was being …
Pharma manufacturing news in brief
November 23, 2010Manufacturing and Production Alpah Biologics, Alpha Biologics, Kemwell, Lonza, Phil Taylor, Roche
Facility updates from Roche, Alpha Biologics, Kemwell and Reinnervate, new contract services from Lonza and Patheon, plus a milestone in …
Roche to develop diagnostic tools for Tarceva
November 23, 2010Sales and Marketing Genzyme, NSCLC, Roche, Tarceva, diagnostic
Roche has obtained a worldwide sub-license from Genzyme to develop a diagnostic kit for the detection of specific mutations for …
Bayer’s challenger to Lucentis shows promise
November 22, 2010Research and Development, Sales and Marketing Bayer, Lucentis, Novartis, Regeneron, Roche, VEGF Trap-Eye, age-related macular degeneration, avastin, wet AMD
Phase III data for a new age-related macular degeneration (wet AMD) treatment show it is as good as Lucentis, the …
Roche set to cut 4,800 jobs worldwide
November 17, 2010Manufacturing and Production, Research and Development, Sales and Marketing Jobs, Roche, avastin, cuts, taspoglutide
Roche’s ‘Operational Excellence’ programme will see it cut 6% of its global workforce over the next two years. The initiative …
Digital Pharma: Diabetes video goes viral
November 16, 2010Medical Communications, Sales and Marketing Diabetes Hands Foundation, Digital Pharma blog, Roche, diabetes, viral video, youtube
An online video encouraging diabetics to test their blood sugar levels has passed 117,000 views on YouTube in just over …
NICE stands firm on Avastin rejection
November 12, 2010Sales and Marketing NICE, Roche, avastin, bevacizumab, colon cancer, metastatic colorectal cancer, patient access scheme
NICE has refused to recommend Roche’s blockbuster cancer drug Avastin for the treatment of metastatic colorectal cancer in its final …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
